Table 2.

Aggregated RR and relative CrI of different treatment options in patients with cardiovascular disease derived from a three-node network meta-analysis.

Intervention		RR (95% CrI) estimates derived from NMA			SUCRA
		PCSK9 monoclonal antibodies vs. placebo	Bempedoic acid vs. placebo	PCSK9 monoclonal antibodies vs. bempedoic acid	PCSK9 monoclonal antibodies	Bempedoic acid	Placebo
Safety outcomes
	New-onset diabetes	1.00 (0.93, 1.07)	0.72 (0.53, 0.99)	1.38 (1.00, 1.92)	0.28	0.97	0.24
	Serious adverse events	0.97 (0.94, 1.01)	1.06 (0.89, 1.27)	0.92 (0.77, 1.10)	0.88	0.22	0.40
	Neurocognitive disorders	0.99 (0.87, 1.13)	0.93 (0.40, 2.30)	1.07 (0.43, 2.49)	0.49	0.57	0.44
Efficacy outcomes
	Composite cardiovascular outcome	0.85 (0.81, 0.90)	0.75 (0.57, 0.99)	1.14 (0.85, 1.51)	0.60	0.89	0.01
	All-cause death	0.94 (0.86, 1.04)	2.53 (0.94, 8.98)	0.37 (0.10, 1.01)	0.93	0.03	0.54
	Cardiovascular death	0.95 (0.84, 1.07)	1.78 (0.52, 8.64)	0.53 (0.11, 1.83)	0.82	0.18	0.50

NMA, network meta-analysis; CrI, credible interval; SUCRA, surface under the cumulative ranking curve; RR, relative risk; PCSK9, proprotein convertase subtilisin/kexintype 9.